AbbVie

AbbVie is a publicly traded biopharmaceutical firm based in the United States that was created in 2013. Abbott Laboratories founded it as a spin-off. TeneoOne and its lead chemical, TNB-383B, were acquired by Abbvie in June 2021. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma.

Despite substantial success by their main competitor in the sector, Vertex, AbbVie remains committed to product development in the cystic fibrosis illness area as of 2019. and expects to lower emissions by 25% by 2025 from a base year of 2015. AbbVie announced plans to evaluate the Kaletra/Aluvia HIV medication as a potential COVID-19 treatment in March 2020. To explore the medication's efficacy, the business formed numerous agreements with health authorities in other nations. However, the medicine was shown to be ineffective in treating severe COVID-19 in the first non-blinded, randomized trial.

Country: USA
Market Cap Value: $202.60 Billion

Website: https://www.abbvie.com/

Facebook: https://www.facebook.com/AbbVieGlobal